Payment overview · 2025
General Payments
$357.20
20 reported records · 7 companies
Healthcare provider profile · identity verified
Elena L Crandell, APRN
Physician Assistants & Advanced Practice Nursing Providers|Nurse Practitioner|Family · CARSON CITY, NV · NPI 1487329421
Verified facts
What the public records show
CMS Open Payments records show Elena L Crandell, APRN received $357.20 in general payments during 2025 across 20 reported records.
ABBVIE INC. accounted for 51.2% of that reported general-payment amount.
The Open Payments records used for this analysis explicitly named 11 associated products.
ABBVIE INC. reported payments to this doctor in 2025. Across the 2025 Open Payments General Payment records loaded for this analysis, that same reporting entity reported SYNTHROID as an associated drug or biological on 10655 records involving 4881 distinct recipient NPIs. Public Medicare Part D data also shows 22 claims for Synthroid by this doctor in 2024.
AstraZeneca Pharmaceuticals LP reported payments to this doctor in 2025. Across the 2025 Open Payments General Payment records loaded for this analysis, that same reporting entity reported FARXIGA as an associated drug or biological on 106133 records involving 42906 distinct recipient NPIs. Public Medicare Part D data also shows 13 claims for Farxiga by this doctor in 2024.
PFIZER INC. reported payments to this doctor in 2025. Across the 2025 Open Payments General Payment records loaded for this analysis, that same reporting entity reported ELIQUIS as an associated drug or biological on 87112 records involving 36032 distinct recipient NPIs. Public Medicare Part D data also shows 15 claims for Eliquis by this doctor in 2024.
These records do not establish that a payment influenced prescribing or medical care.
Separate record types
Research & Ownership
Research Payments (direct recipient): not present in the loaded data
Associated Research Funding (for example, named PI): not present in the loaded data
Ownership / Investment: not present in the loaded data
These categories are never added into the General Payments headline. Associated research funding must not be described as money the doctor personally received unless the source record supports that conclusion.
Who paid this doctor?
Companies in 2025 General Payments
| Reported company | Canonical company | Amount | Share | Records | Year |
|---|---|---|---|---|---|
| ABBVIE INC. | Unresolved — no canonical attribution shown | $183.08 | 51.2% | 12 | 2025 |
| PFIZER INC. | Unresolved — no canonical attribution shown | $52.95 | 14.8% | 2 | 2025 |
| Merck Sharp & Dohme LLC | Unresolved — no canonical attribution shown | $36.16 | 10.1% | 2 | 2025 |
| ITI, Inc. (d/b/a Intra-Cellular Therapies, Inc.) | Unresolved — no canonical attribution shown | $28.33 | 7.9% | 1 | 2025 |
| AstraZeneca Pharmaceuticals LP | Unresolved — no canonical attribution shown | $20.80 | 5.8% | 1 | 2025 |
| Xeris Pharmaceuticals, Inc. | Unresolved — no canonical attribution shown | $18.14 | 5.1% | 1 | 2025 |
| Daiichi Sankyo Inc. | Unresolved — no canonical attribution shown | $17.74 | 5.0% | 1 | 2025 |
What were the payments for?
Payment categories
| Category | Amount | Records |
|---|---|---|
| Food and Beverage | $357.20 | 20 |
A meal, consulting fee, royalty, and travel payment describe different kinds of reported relationships and should not be interpreted as equivalent.
Analysis 1 · Payment-linked products
Products named in Open Payments records
| Reported product | Type | Reported company | Related amount* | Records | Year |
|---|---|---|---|---|---|
| VRAYLAR Normalized: vraylar |
Drug | ABBVIE INC. | $183.08 | 12 | 2025 |
Source payment records
|
|||||
| ABRYSVO Normalized: abrysvo |
Biological | PFIZER INC. | $52.95 | 2 | 2025 |
Source payment records
|
|||||
| COMIRNATY Normalized: comirnaty |
Biological | PFIZER INC. | $52.95 | 2 | 2025 |
Source payment records
|
|||||
| PREVNAR 20 Normalized: prevnar 20 |
Biological | PFIZER INC. | $52.95 | 2 | 2025 |
Source payment records
|
|||||
| CAPVAXIVE Normalized: capvaxive |
Biological | Merck Sharp & Dohme LLC | $36.16 | 2 | 2025 |
Source payment records
|
|||||
| GARDASIL 9 Normalized: gardasil 9 |
Biological | Merck Sharp & Dohme LLC | $36.16 | 2 | 2025 |
Source payment records
|
|||||
| CAPLYTA Normalized: caplyta |
Drug | ITI, Inc. (d/b/a Intra-Cellular Therapies, Inc.) | $28.33 | 1 | 2025 |
Source payment records
|
|||||
| BREZTRI Normalized: breztri |
Drug | AstraZeneca Pharmaceuticals LP | $20.80 | 1 | 2025 |
Source payment records
|
|||||
| GVOKE HYPOPEN Normalized: gvoke hypopen |
Drug | Xeris Pharmaceuticals, Inc. | $18.14 | 1 | 2025 |
Source payment records
|
|||||
| INJECTAFER Normalized: injectafer |
Drug | Daiichi Sankyo Inc. | $17.74 | 1 | 2025 |
Source payment records
|
|||||
| M-M-R II Normalized: m m r ii |
Biological | Merck Sharp & Dohme LLC | $16.24 | 1 | 2025 |
Source payment records
|
|||||
* Product-associated amounts are non-additive because one payment record may name more than one product.
These products were named on specific Open Payments records. A named product does not show that the payment influenced treatment or prescribing.
Public prescribing for products named in payments
No exact normalized or approved-alias overlap was found in the loaded Part D year. This does not mean the doctor never prescribed the product.
The presence of the same drug in both datasets does not show that a payment caused or influenced a prescription.
Analysis 2 · Same-company prescribing overlap
Drugs reported in other payments from the same company that also appear in Medicare Part D
This analysis is independent from products named on this doctor’s individual payment records. A row appears only when the exact Open Payments reporting entity paid this doctor, that same reporting entity reported the drug or biological on at least 10 loaded General Payment records involving at least 2 distinct recipient NPIs, and this doctor has the same non-generic brand in public Part D data. This does not mean the company owns or manufactures the drug.
| Paying company | Payment year | Drug reported by same entity | Open Payments evidence | Part D | Claims | Beneficiaries |
|---|---|---|---|---|---|---|
| ABBVIE INC. Exact reporting entity; no affiliate inference |
2025 | SYNTHROID open payments reported associated product |
CMS Open Payments — General Payments 10655 supporting records · 4881 recipient NPIs · example record 1201352636 |
Synthroid · 2024 Exact normalized brand match · 1 Part D row |
22 | suppressed by CMS |
| AstraZeneca Pharmaceuticals LP Exact reporting entity; no affiliate inference |
2025 | FARXIGA open payments reported associated product |
CMS Open Payments — General Payments 106133 supporting records · 42906 recipient NPIs · example record 1206131362 |
Farxiga · 2024 Exact normalized brand match · 1 Part D row |
13 | suppressed by CMS |
| PFIZER INC. Exact reporting entity; no affiliate inference |
2025 | ELIQUIS open payments reported associated product |
CMS Open Payments — General Payments 87112 supporting records · 36032 recipient NPIs · example record 1228794063 |
Eliquis · 2024 Exact normalized brand match · 1 Part D row |
15 | suppressed by CMS |
These facts do not show that a payment was for the drug, that the company owns or manufactures the drug, or that a payment caused or influenced prescribing.
Public Medicare Part D data
Provider-and-drug rows loaded for 2024
| Brand | Generic | Claims | Beneficiaries |
|---|---|---|---|
| Levothyroxine Sodium | Levothyroxine Sodium | 165 | 74 |
| Atorvastatin Calcium | Atorvastatin Calcium | 152 | 67 |
| Lisinopril | Lisinopril | 148 | 60 |
| Rosuvastatin Calcium | Rosuvastatin Calcium | 142 | 64 |
| Losartan Potassium | Losartan Potassium | 117 | 49 |
| Amlodipine Besylate | Amlodipine Besylate | 99 | 42 |
| Omeprazole | Omeprazole | 81 | 30 |
| Metformin Hcl | Metformin Hcl | 65 | 34 |
| Trazodone Hcl | Trazodone Hcl | 64 | 29 |
| Metformin Hcl Er | Metformin Hcl | 58 | 24 |
| Gabapentin | Gabapentin | 50 | 27 |
| Hydrochlorothiazide | Hydrochlorothiazide | 48 | 20 |
| Tamsulosin Hcl | Tamsulosin Hcl | 48 | 21 |
| Pantoprazole Sodium | Pantoprazole Sodium | 47 | 21 |
| Simvastatin | Simvastatin | 46 | 21 |
| Albuterol Sulfate Hfa | Albuterol Sulfate | 44 | 27 |
| Alendronate Sodium | Alendronate Sodium | 43 | 17 |
| Montelukast Sodium | Montelukast Sodium | 38 | 16 |
| Duloxetine Hcl | Duloxetine Hcl | 37 | 13 |
| Potassium Chloride | Potassium Chloride | 36 | 13 |
| Furosemide | Furosemide | 33 | 11 |
| Carvedilol | Carvedilol | 32 | suppressed |
| Meloxicam | Meloxicam | 32 | 12 |
| Hydroxyzine Hcl | Hydroxyzine Hcl | 30 | suppressed |
| Ozempic | Semaglutide | 30 | suppressed |
| Atenolol | Atenolol | 28 | 11 |
| Cyclobenzaprine Hcl | Cyclobenzaprine Hcl | 28 | 13 |
| Fluoxetine Hcl | Fluoxetine Hcl | 26 | suppressed |
| Ondansetron Odt | Ondansetron | 26 | 14 |
| Metoprolol Succinate | Metoprolol Succinate | 25 | 12 |
| Citalopram Hbr | Citalopram Hydrobromide | 24 | suppressed |
| Tizanidine Hcl | Tizanidine Hcl | 23 | suppressed |
| Synthroid | Levothyroxine Sodium | 22 | suppressed |
| Fluticasone Propionate | Fluticasone Propionate | 21 | suppressed |
| Ropinirole Hcl | Ropinirole Hcl | 21 | suppressed |
| Estradiol | Estradiol | 18 | suppressed |
| Ezetimibe | Ezetimibe | 18 | suppressed |
| Allopurinol | Allopurinol | 17 | suppressed |
| Sertraline Hcl | Sertraline Hcl | 17 | suppressed |
| Triamcinolone Acetonide | Triamcinolone Acetonide | 17 | 14 |
| Escitalopram Oxalate | Escitalopram Oxalate | 16 | suppressed |
| Pravastatin Sodium | Pravastatin Sodium | 16 | suppressed |
| Eliquis | Apixaban | 15 | suppressed |
| Finasteride | Finasteride | 15 | suppressed |
| Jardiance | Empagliflozin | 15 | suppressed |
| Sulfamethoxazole-Trimethoprim | Sulfamethoxazole/Trimethoprim | 15 | 13 |
| Valsartan | Valsartan | 15 | suppressed |
| Benazepril Hcl | Benazepril Hcl | 14 | suppressed |
| Cephalexin | Cephalexin | 14 | 14 |
| Chlorthalidone | Chlorthalidone | 14 | suppressed |
| Losartan-Hydrochlorothiazide | Losartan/Hydrochlorothiazide | 14 | suppressed |
| Metoprolol Tartrate | Metoprolol Tartrate | 14 | suppressed |
| Mounjaro | Tirzepatide | 14 | suppressed |
| Celecoxib | Celecoxib | 13 | suppressed |
| Farxiga | Dapagliflozin Propanediol | 13 | suppressed |
| Paroxetine Hcl | Paroxetine Hcl | 13 | suppressed |
| Zolpidem Tartrate | Zolpidem Tartrate | 13 | suppressed |
| Prednisone | Prednisone | 12 | 11 |
| Spironolactone | Spironolactone | 12 | suppressed |
| Tradjenta | Linagliptin | 12 | suppressed |
| Valacyclovir | Valacyclovir Hcl | 12 | suppressed |
| Venlafaxine Hcl Er | Venlafaxine Hcl | 12 | suppressed |
| Hydroxyzine Pamoate | Hydroxyzine Pamoate | 11 | suppressed |
| Ibuprofen | Ibuprofen | 11 | suppressed |
| Lovastatin | Lovastatin | 11 | suppressed |
Timeline
Payment and prescribing data by year
Open Payments and Medicare Part D may refer to different years. They are shown separately rather than aligned as if they describe the same period.
| Year | General Payments | Main payer | Explicit products | Company overlaps | Part D coverage |
|---|---|---|---|---|---|
| 2025 | $357.20 · 20 records | ABBVIE INC. | ABRYSVO, BREZTRI, CAPLYTA, CAPVAXIVE, COMIRNATY, GARDASIL 9, GVOKE HYPOPEN, INJECTAFER, M-M-R II, PREVNAR 20, VRAYLAR | 3 | — |
| 2024 | — | — | — | — | Complete |
Questions to ask
Questions you could discuss with your doctor
- How do you evaluate evidence when you have a financial relationship with ABBVIE INC.?
- Are there reasonable alternatives I should understand when we discuss treatment options?
- How should I interpret the industry-payment records shown here in the context of my care?
These are general questions generated from reviewed templates. They are not personalized medical advice.
Sources and limitations
How to read this page
- Payment and Medicare prescribing data can cover different years; every comparison shows both years explicitly.
- Part D does not represent a doctor’s entire practice; it excludes many patients and is subject to CMS public-release thresholds.
- Company–drug relationships must have an auditable source, a precise relationship type, and a valid evidence period. Unresolved mappings are not published.
- Generic drug claims are not attributed to a specific manufacturer without manufacturer-level evidence.
- When a source extract is incomplete, missing rows are never treated as proof of no payments or no prescriptions.
Loaded source releases
| Dataset | Year | Publication | Source |
|---|---|---|---|
| CMS Open Payments — General Payments | 2025 | 2026-06-30 | Original source |
| Medicare Part D Prescribers by Provider and Drug | 2024 | 2026-05-06 | Original source |
| NPPES Data Dissemination V2 | current / reference data | 2026-08-10 | Original source |
Full methodology · Questions & answers · Report a possible error